0001821825-24-000044.txt : 20240403
0001821825-24-000044.hdr.sgml : 20240403
20240403184043
ACCESSION NUMBER: 0001821825-24-000044
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20240331
FILED AS OF DATE: 20240403
DATE AS OF CHANGE: 20240403
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Weaver Kirke
CENTRAL INDEX KEY: 0001959622
ORGANIZATION NAME:
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-40235
FILM NUMBER: 24820731
MAIL ADDRESS:
STREET 1: 30 HUDSON STREET
STREET 2: FLOOR 33
CITY: JERSEY CITY
STATE: NJ
ZIP: 07302
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Organon & Co.
CENTRAL INDEX KEY: 0001821825
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
ORGANIZATION NAME: 03 Life Sciences
IRS NUMBER: 464838035
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 30 HUDSON STREET
STREET 2: FL 33
CITY: JERSEY CITY
STATE: NJ
ZIP: 07302
BUSINESS PHONE: 551-430-6000
MAIL ADDRESS:
STREET 1: 30 HUDSON STREET
STREET 2: FL 33
CITY: JERSEY CITY
STATE: NJ
ZIP: 07302
4
1
wk-form4_1712184027.xml
FORM 4
X0508
4
2024-03-31
0
0001821825
Organon & Co.
OGN
0001959622
Weaver Kirke
C/O ORGANON & CO.
30 HUDSON STREET, FLOOR 33
JERSEY CITY
NJ
07302
0
1
0
0
Gen. Counsel & Corp. Secy.
0
Common Stock
2024-03-31
4
M
0
4294
0
A
22825
D
Common Stock
2024-03-31
4
F
0
1224
18.80
D
21601
D
Common Stock
2024-03-31
4
M
0
6200
0
A
27801
D
Common Stock
2024-03-31
4
F
0
1767
18.80
D
26034
D
Common Stock
2024-03-31
4
M
0
3125
0
A
29159
D
Common Stock
2024-03-31
4
F
0
891
18.80
D
28268
D
Restricted Stock Units
2024-03-31
4
M
0
4294
0
D
Common Stock
4294
4294
D
Restricted Stock Units
2024-03-31
4
M
0
3125
0
D
Common Stock
3125
3125
D
Restricted Stock Units
2024-03-31
4
M
0
6200
0
D
Common Stock
6200
12400
D
Each Restricted Stock Unit converts into one share of Organon & Co. ("Organon") common stock.
The Reporting Person was granted restricted stock units ("RSUs"), which represent a contingent right to receive one share of Organon common stock for each RSU. On each of March 31, 2023, and March 31, 2024, one-third of the RSUs vested, with the remaining RSUs to vest on March 31, 2025.
The Reporting Person was granted RSUs on November 7, 2022, which represent a contingent right to receive one share of Organon common stock for each RSU. On each of March 31, 2023, and March 31, 2024, one-third of the RSUs vested, with the remaining RSUs to vest on March 31, 2025.
The Reporting Person was granted RSUs on March 31, 2023. On March 31, 2024, one-third of the RSUs vested with the remaining RSUs to vest in two equal installments on March 31, 2025 and March 31, 2026.
/s/ Tarnetta V. Jones, as Attorney-in-Fact for Kirke Weaver
2024-04-03